作者
Hisham A Badreldin, Ghazwa B Korayem, Basel A Alenazy, Mousa H Aljohani, Omar A Alshaya, Khalid Al Sulaiman, Lolwa Alabdelmuhsin, Huda Alenazi, Dahlia M Almutairi, Faisal Alanazi, Seba K Alobathani, Ghada M Alqannam, Ohoud Almadani, Ohoud Aljuhani, Awatif Hafiz, Ghalyah Aljowaie, Ehssan Basha, Tariq Alqahtani, Mosaad Alhussein
发表日期
2023/12/22
期刊
Medicine
卷号
102
期号
51
页码范围
e36699
出版商
LWW
简介
Despite the demonstrated advantages of angiotensin receptor/neprilysin inhibitors in the management of heart failure, the pivotal Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF) trial, which explored this class of medications, did not include individuals from Saudi Arabia. Recognizing that different nations and ethnic groups may exhibit unique characteristics, this study aimed to compare the demographics and outcomes of patients in Saudi Arabia who received sacubitril/valsartan (Sac/Val) with those enrolled in the PARADIGM-HF trial. In this retrospective, multicenter cohort study, we included all adult patients diagnosed with heart failure with reduced ejection fraction (HFrEF) within a tertiary healthcare system in Saudi Arabia between January 2018 and December 2021 and were initiated on Sac/Val. The primary objective was to compare the patient characteristics of those …
学术搜索中的文章
HA Badreldin, GB Korayem, BA Alenazy, MH Aljohani… - Medicine, 2023